Biomarker-Integrated Umbrella, Advanced Gastric Cancer

Not Applicable

Completed

• Conditions: Gastric Cancer
• Interventions: Other: biomarker screening

• Registration Number: NCT02951091
• Lead Sponsor: Yonsei University

Brief Summary

In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.

The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.

Detailed Description

In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.

Study Timeline

• Study Start: 2016-01-01
• Study First Submitted: 2016-10-28
• Study First Submitted QC: 2016-10-31
• Study First Posted: 2016-11-01
• Primary Completion: 2021-12
• Status Verified: 2024-01
• Study Completion: 2024-03
• Last Update Submitted: 2024-12-26
• Last Update Posted: 2024-12-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

1. Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and gastroesophageal junction cancer

2. Eastern Cooperative Oncology Group performance status of 0 to 1

3. Male or female; ≥ 19 years of age

4. On or progression after 1st line palliative chemotherapy

5. Subjects with evaluable lesion (using RECIST 1.1 criteria)

6. Subjects who meet the following criteria:

   • Absolute neutrophil count ≥ 1000 /µL
   • Platelet count ≥ 75,000/ µL
   • Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance ≥60 mL/min
   • aspartate aminotransferase and alanine transaminase 3 x upper limit of normal

Read More

Exclusion Criteria

• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
biomarker group	biomarker screening	400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets \[Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN\] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
control group	biomarker screening	Patients will be randomized to the biomarker vs control group (standard of care; paclitaxel) as 4:1 ratio.

Primary Outcome Measures

Name	Time	Method
progression free survival	6 weeks	progression free survival

Trial Locations

Locations (1)

Severance Hospital, Yonsei University Health System, Yonsei Cancer Center; 🇰🇷 Seoul, Korea, Republic of